A 1,000-Year-Old Chinese Herb May Finally Have a Scientific Case for Treating Hair Loss

For centuries, practitioners of traditional Chinese medicine described a root called Polygonum multiflorum as able to "blacken hair and nourish essence." That language sounds like folklore until you map it against contemporary hair biology and notice how precisely it lines up. A new scientific review, published in the Journal of Holistic Integrative Pharmacy and led by first author Han Bixian, does exactly that mapping, and the overlap is striking enough to warrant serious attention, even if the clinical evidence needed to confirm it hasn't been assembled yet.

Polygonum multiflorum targets multiple hair-loss pathways at once

Androgenetic alopecia (AGA), the most common form of hair loss, works through a well-understood mechanism: the hormone dihydrotestosterone (DHT) binds to receptors in hair follicles, progressively shrinking them until they produce only fine, colorless vellus hairs or stop producing hair entirely. The two drugs most widely prescribed against AGA, finasteride and minoxidil, each target a single point in this process. Finasteride suppresses DHT production; minoxidil, applied topically, dilates blood vessels to encourage growth. Neither is a complete answer, and limitations of current hair loss drugs like sexual dysfunction from finasteride and scalp irritation from minoxidil push many patients to look elsewhere.

The review's central claim is that Polygonum multiflorum appears to act on at least four distinct biological routes simultaneously. It may block DHT from binding to follicle receptors, activate the Wnt and Sonic Hedgehog (Shh) signaling pathways that drive the hair growth cycle, protect follicle cells from premature apoptosis (programmed cell death), and boost blood flow to the scalp, which delivers the oxygen and nutrients follicles need to sustain growth. No single approved drug addresses all four of these at once, which is part of what makes the herb scientifically interesting.

Who stands to benefit if the evidence holds up

AGA affects a substantial share of the global population, with prevalence rising steeply with age in both men and women. The condition is not medically dangerous, but its psychological impact is well documented: it correlates with reduced self-esteem, increased anxiety, and in some cases clinical depression. Patients who cannot tolerate finasteride's hormonal side effects or who see only modest results from minoxidil have limited alternatives, and many turn to unproven supplements or costly procedures like hair transplantation.

If Polygonum multiflorum's multi-pathway activity is confirmed in rigorous human trials, it could offer a meaningful addition to that limited toolkit, particularly for patients seeking a treatment with fewer systemic hormonal effects. The broader landscape of TCM approaches to hair loss has received growing attention for exactly this reason: herbal compounds often carry multiple active constituents that work across interconnected biological networks rather than at a single molecular target.

How the review was constructed

Han Bixian and colleagues did not conduct a clinical trial. Instead, they synthesized multiple categories of existing evidence: laboratory studies examining the herb's effects on follicle cell lines and animal models, clinical case reports, and historical herbal records stretching back to the Tang Dynasty. The review's methodological move was to look for convergence, places where the traditional descriptions of the herb's effects predicted what modern molecular biology would later discover.

That convergence, the researchers argue, is not coincidental. "Our analysis bridges ancient wisdom and modern science," Han Bixian wrote. "What surprised us was how consistently historical texts, from the Tang Dynasty onward, described effects that align perfectly with today's understanding of hair biology. Modern studies now confirm that this isn't folklore; it's pharmacology."

The review also emphasizes that preparation matters considerably. Polygonum multiflorum is typically processed before use in traditional medicine, a step the authors say is important both for reducing potential toxicity and for optimizing the herb's biological activity. Properly processed preparations showed a more favorable safety profile in the studies surveyed.

Liver toxicity concerns and the limits of current data

The herb is not without controversy. Polygonum multiflorum has been associated with cases of drug-induced liver injury in published reports, and several regulatory agencies have issued warnings about unprocessed or improperly dosed preparations. The review acknowledges this directly, noting that natural products are not automatically safe and that effects vary substantially based on preparation method, dose, and quality control.

More fundamentally, the review cannot substitute for the large, carefully designed randomized controlled trials that would be needed to confirm efficacy and safety across diverse patient populations. The studies synthesized here are, in many cases, small, preclinical, or based on case reports rather than controlled interventions. Integrating traditional and complementary medicine into standard care faces persistent challenges including undeveloped regulatory frameworks and insufficient large-scale research data, and Polygonum multiflorum is no exception. The review's authors are explicit that they are not recommending self-treatment and that professional guidance is essential.

The path toward clinical validation

The immediate next step for this line of research is clear: large, controlled human trials that test standardized preparations of Polygonum multiflorum against placebo or against existing treatments like minoxidil, with pre-specified safety monitoring for liver function. Those trials do not yet exist in a form sufficient to change clinical practice.

What the review contributes is a mechanistic framework that makes those trials worth running. By mapping the herb's known molecular actions onto the established biology of AGA, it gives researchers a hypothesis to test and a rationale for which preparations and doses are most likely to be both active and safe. Broader advances in plant-based alopecia therapies, including improved drug delivery systems and standardized extraction methods, may help translate that framework into testable interventions faster than traditional clinical development pipelines would allow.

For patients dealing with hair loss today, the honest message from this review is hopeful but modest: a plant used for over a millennium appears to have a plausible biological basis for its traditional reputation, and researchers are starting to take it seriously. That is genuinely interesting. It is not yet a treatment.

Evidence rating

INVESTIGATIONAL — 57/100

Narrative review synthesizing laboratory studies, historical herbal records, and limited clinical observations on Polygonum multiflorum for androgenetic alopecia. No randomized controlled trial is presented; the evidence base does not establish causation. The authors themselves note that large, well-designed human trials are still needed before efficacy or safety can be confirmed across patient populations.